Cue® helps the nation's premiere
high school basketball showcase return to in-person
action
SAN
DIEGO, March 28, 2022 /PRNewswire/ -- Cue Health
("Cue") (Nasdaq: HLTH), the healthcare technology company behind
the country's most accurate at-home COVID-19 test*, today announced
that its COVID-19 test will be the preferred on-site test to help
support the health and safety of the student-athletes and staff at
the 2022 McDonald's All American Games. The Games will celebrate 45
years of showcasing basketball's brightest young stars by returning
to in-person action in Chicago
tomorrow, March 29.
Cue's test uses molecular nucleic acid amplification technology
(NAAT), providing lab-quality results directly to a user's
connected mobile device in about 20 minutes. The test can detect
all known COVID-19 variants of concern and can be used on adults
and children (age 2 years and over for OTC/home use and under 2
years for professional use), with or without symptoms.
"The McDonald's All American Games is the gold standard in high
school basketball, and we are proud to support the health and
safety of its athletes, staff, and fans with Cue's gold standard
diagnostic solution that meets a growing need for highly accurate,
fast, and reliable on-site testing," said Chris Achar, Chief Strategy Officer of Cue
Health.
Last month, Cue announced a partnership with former McDonald's
All American and three-time NBA All-Star Karl-Anthony Towns to donate $250,000 of Cue Readers and COVID-19 tests to
public schools in Towns' home state of New Jersey and Minneapolis, Karl-Anthony's home throughout
his entire playing career.
The McDonald's All American Games is one of several major live
sporting events to which Cue provides its testing solution. Cue has
also supported sports leagues, including the National Basketball
Association and Major League Baseball. In addition, many leading
healthcare organizations and distributors across the country use
Cue, including Johns Hopkins Medicine, Mayo Clinic, and UPMC
Children's Community Pediatrics, among others.
Cue's COVID-19 OTC Test is available at shop.cuehealth.com and
can be purchased a la carte or through its Cue+™ membership model.
In addition to the most accurate at-home COVID-19 test available,
Cue+ offers benefits such as access to 24/7 virtual care,
prescription services, same-day delivery in select markets, and
supervised testing by virtual proctor, which meets CDC requirements
for international travel to the U.S..
*Based on clinical study results submitted to FDA for other
EUA molecular home tests.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easy for individuals to access health information and
places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, regulatory
approval from India's Central
Drugs Standard Control Organization, and PSAR authorization from
Singapore's Health Sciences
Authority. Cue was founded in 2010 and is headquartered in
San Diego. For more information,
please visit www.cuehealth.com.
Forward-Looking
Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements". The words, without limitation,
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including those related to the expected future diagnostic
test menu and the factors discussed in the "Risk Factors" section
of the Form 10-Q dated November 10,
2021 filed by Cue with the SEC. Any forward-looking
statements contained in this press release are based on the current
expectations of Cue's management team and speak only as of the date
hereof, and Cue specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
These products have not been FDA cleared or approved; but have
been authorized by FDA under an Emergency Use Authorization (EUA).
These products have been authorized only for the detection of
nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens. The emergency use of these products is only authorized
for the duration of the declaration that circumstances exist
justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cue-health-serves-as-preferred-testing-provider-for-the-2022-mcdonalds-all-american-games-301511588.html
SOURCE Cue Health Inc.